178 related articles for article (PubMed ID: 22370803)
1. [Off-label therapy of rheumatoid arthritis and spondyloarthritis].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):122-4, 126. PubMed ID: 22370803
[TBL] [Abstract][Full Text] [Related]
2. [Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
Brandt-Jürgens J
Z Rheumatol; 2013 Mar; 72(2):114-6. PubMed ID: 23223912
[No Abstract] [Full Text] [Related]
3. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
4. [The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
Hellmich B; Gross WL
Z Rheumatol; 2003 Feb; 62(1):34-5. PubMed ID: 12624800
[No Abstract] [Full Text] [Related]
5. [Rheumatoid arthritis: milestones in classification and treatment].
Fiehn C
Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
[TBL] [Abstract][Full Text] [Related]
6. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
Janzen RW; Ludwig WD;
Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
[TBL] [Abstract][Full Text] [Related]
7. [Off-label therapy from the perspective of the medical insurance service].
Grell L; Rieger M
Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
[TBL] [Abstract][Full Text] [Related]
8. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
9. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Pharmacoeconomics; 2002; 20(1):61-70. PubMed ID: 11817993
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
[TBL] [Abstract][Full Text] [Related]
11. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Singer O; Gibofsky A
Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
[TBL] [Abstract][Full Text] [Related]
14. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Perdan-Pirkmajer K; Hočevar A; Rotar Ž; Žibert J; Marolt VF; Gučev F; Tomšič M
Rheumatol Int; 2013 Nov; 33(11):2885-8. PubMed ID: 22955878
[TBL] [Abstract][Full Text] [Related]
16. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
17. [Solutions for off-label therapy].
Schmidt WA
Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.
Mroczkowski PJ; Weinblatt ME; Kremer JM
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S66-8. PubMed ID: 10589360
[TBL] [Abstract][Full Text] [Related]
20. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
